Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 4 stocks made the list for top value stocks in the Biotechnology & Medical Research industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Why Focus on Undervalued Biotechnology & Medical Research Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

4 Undervalued Biotechnology & Medical Research Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Biotechnology & Medical Research industry for Wednesday, March 06, 2024. Let’s take a closer look at their individual scores to see how they measure up against each other and the Biotechnology & Medical Research industry median.

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

International Stem Cell Corp’s Value Grade

Value Grade:

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company's products are based on human cell culture and a type of pluripotent stem cells and human parthenogenetic stem cells (hpSCs). The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of hpSCs for the treatment of various diseases of the central nervous system and liver diseases. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D;) for the therapeutic market.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

International Stem Cell Corp has a Value Score of 81, which is considered to be undervalued.

When you look at International Stem Cell Corp’s price-to-sales ratio at 0.10 compared to the industry median at 8.92, this company has a lower price relative to revenue compared to its peers. This could make International Stem Cell Corp’s stock more attractive for value investors.

International Stem Cell Corp’s price-earnings ratio is 4.11 compared to the industry median at 27.97. This means it has a lower share price relative to earnings compared to its peers. This could make International Stem Cell Corp more attractive for value investors.

Now, let’s assess International Stem Cell Corp’s EV/EBITDA ratio, also known as enterprise multiple. At 365.0, when compared to the industry median of 0.9, the company may be considered overvalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. International Stem Cell Corp’s shareholder yield is higher than its industry median ratio of (9.92%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

Lastly, let’s take a look at International Stem Cell Corp’s price-to-free-cash-flow ratio (P/FCF), which can indicate a company’s market value relative to its operating cash flow. International Stem Cell Corp’s price-to-free-cash-flow ratio is lower than its industry median ratio of 22.21. This could make International Stem Cell Corp more attractive because the lower P/FCF ratio indicates that International Stem Cell Corp is undervalued. The P/FCF ratio metric can also be viewed over a long-term time frame to see if the company's cash flow to share price value is generally improving or worsening.

Lumos Pharma Inc’s Value Grade

Value Grade:

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Lumos Pharma Inc has a Value Score of 79, which is considered to be undervalued.

Lumos Pharma Inc’s price-to-book ratio is higher than its peers. This could make Lumos Pharma Inc less attractive for value investors when compared to the industry median at 2.10.

You can read more about Lumos Pharma Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

P3 Health Partners Inc’s Value Grade

Value Grade:

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company transforms healthcare by improving the lives of both patients and providers led by physicians. The Company has an expansive network of approximately 2,800 affiliated primary care providers across the country. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the Company creates an enhanced patient experience by navigating, coordinating, and integrating the patient?s care within the healthcare system. The Company serves Arizona, Nevada, Florida, Oregon, California, and more. The Company offers P3 care model that consists of education, tools, and support to manage illness, prevention and wellness support, medication management, nursing support, access to community resources and services, and transition of care teams.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

P3 Health Partners Inc has a Value Score of 66, which is considered to be undervalued.

P3 Health Partners Inc’s price-to-book ratio is higher than its peers. This could make P3 Health Partners Inc less attractive for value investors when compared to the industry median at 2.10.

You can read more about P3 Health Partners Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Petros Pharmaceuticals Inc’s Value Grade

Value Grade:

Petros Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on men?s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It commercializes therapeutics for men's health issues, such as endothelial dysfunction, psychosexual and psychosocial ailments, hormone health, and substance-use disorders. It also commercializes and develops Stendra, a PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, it has a global license (the Hybrid License) to develop and commercialize H100, a novel and patented topical formulation candidate for the treatment of acute Peyronies disease.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Petros Pharmaceuticals Inc has a Value Score of 91, which is considered to be undervalued.

Petros Pharmaceuticals Inc’s price-to-book ratio is higher than its peers. This could make Petros Pharmaceuticals Inc less attractive for value investors when compared to the industry median at 2.10.

You can read more about Petros Pharmaceuticals Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Other Biotechnology & Medical Research Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology & Medical Research stocks as well as other industrys.

Choosing Which of the 4 Best Biotechnology & Medical Research Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

• International Stem Cell Corp stock has a Value Grade of A.
• Lumos Pharma Inc stock has a Value Grade of B.
• P3 Health Partners Inc stock has a Value Grade of B.
• Petros Pharmaceuticals Inc stock has a Value Grade of A.

Now that you have a bit more background about each of the 4 undervalued stocks in the Biotechnology & Medical Research industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Additional Resources About Biotechnology & Medical Research Stocks

Want to learn more about Biotechnology & Medical Research stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

• 4 Undervalued Biotechnology & Medical Research Stocks for Wednesday, March 06
• 6 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 05
• What You Need to Know About 2Seventy Bio Inc's Q4 Earnings
• Which Is a Better Investment, Alpine Immune Sciences Inc or PTC Therapeutics, Inc. Stock?

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.